论文部分内容阅读
目的：人参、麦冬因可提高过氧化物歧化酶（ＳＯＤ）活性，直接清除自由基，对缺血脑组织有保护作用，故用来治疗早期脑梗死，以观察其疗效。方法：在临床上选取早期脑梗死患者，随机分为两组，每组４５例。治疗组用综合治疗加参麦注射液，对照组用综合治疗加复方丹参注射液，采取双盲对照一并用全国第四届脑血管病学术会议通过的《脑卒中患者临床神经功能缺损程度评分标准》［１］进行疗效评定。结果：参麦治疗早期脑梗死患者１５天疗效好于对照组。结论：参麦注射液治疗脑梗死疗效好，无副作用。
OBJECTIVE: Ginseng and Ophiopogon can be used to treat early cerebral infarction to improve the activity of superoxide dismutase (SOD) and directly scavenge free radicals and protect the ischemic brain tissue. Methods: The patients with early cerebral infarction were randomly divided into two groups (45 cases in each group). The treatment group combined with Shenmai injection, the control group with comprehensive treatment plus compound Danshen injection, double-blind control taken together with the Fourth National Conference on Cerebrovascular Disease adopted by the “stroke patients clinical neurological deficit score ”[1] for efficacy evaluation. Results: Shenmai treatment of patients with early cerebral infarction 15 days better than the control group. Conclusion: Shenmai injection is effective in treating cerebral infarction with no side effects.